FDA Grants Orphan Drug Designation to Investigational CAR T-Cell Agent in Gastric/GEJ Cancer
The FDA granted Orphan Drug designation to CARsgen Therapeutics for a CAR T-cell treatment it’s developing to treat gastric cancer.
CAR T Cells Show Activity in Solid Tumors
Gastric cancer patients in a trial responded to a CAR-T therapy targeting a molecule found in epithelial cells called claudin 18.2. Additional... Read More